FKONCO

Fresenius Kabi Oncology Limited has informed the Exchange regarding the Outcome of Board Meeting of the Company held on May 27, 2013.

Fresenius Kabi Oncology Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 30, 2012, inter alia, has approved / took note of the following: (1) Not recommended any dividend for the financial year 2011-12, (2) Recommended the re-appointment of Dr. Naresh Trehan as a Director liable to retire by rotation, (3) Recommended the re-appointment of Mr. Dilip G. Shah as a Director liable to retire by rotation, (4) Recommended the re-appointment of Mr. Rakesh Bhargava as a Director liable to retire by rotation, (5) Recommended the appointment of Mr. P

Fresenius Kabi Oncology Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on February 02, 2012, has taken on record the resignation of Dr. Anand C. Burman as the Non - Executive Director of the Company w.e.f. February 02, 2012.

Fresenius Kabi Oncology Limited has informed the Exchange that the Board of Directors at its meeting held on May 26, 2011 has: (1) Not recommended any dividend for the year. (2) Recommended the re-appointment of Dr. Michael Schonhofen as a Director liable to retire by rotation.(3) Recommended the re-appointment of Mr. Nitin Potdar as a Director liable to retire by rotation. (4) Recommended the re-appointment of Mr. Gerrit Steen as a Director liable to retire by rotation.(5) Recommended the appointment of Mr. Mats Christer Henriksson as a Director liable to retire by rotation in terms of Sectio

Fresenius Kabi Oncology Limited has informed the Exchange that the Board of Directors at its meeting held on May 28, 2010 has: (1) Decided to convene the Annual General Meeting of the Company on July 29, 2010. (2) Not recommended any dividend for the year. (3) Recommended the re-appointment of Dr. Anand C. Burman as a Director liable to retire by rotation.(4) Recommended the re-appointment of Mr. Dilip G. Shah as a Director liable to retire by rotation. (5) Recommended the re-appointment of Mr. Rakesh Bhargava as a Director liable to retire by rotation.

Dabur Pharma Limited has informed the Exchange regarding outcome of recently concluded second Board of Directors Meeting of the Company held on August 11, 2008. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/DaburPharma_OutcomeofBM_11082008_01.zip target=NEW> For more details click here.</a>

Dabur Pharma Limited has informed the Exchange regarding outcome of recently concluded Board of Directors Meeting of the Company held on August 11, 2008. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/DaburPharma_OutcomeofBM_11082008.zip target=NEW> For more details click here.</a>

Dabur Pharma Limited has informed the Exchange that: "The Board of Directors of Dabur Pharma Limited at its meeting held on 31st January, 2007 decided to sell / dispose off / transfer the "Non Oncology Formulations Divisions" to Alembic Limited for a consideration of Rs. 1,59,00,00,000/- (Rupees One Hundred Fifty Nine Crores Only) plus Net Working Capital as of 1st April, 2007 and other terms and conditions as per the agreement between the parties. This deal is subject to shareholders and other regulatory / statutory approvals as may be required. Pursuant to Section 192A of the Companies Act,

Dabur Pharma Limited has informed the Exchange on January 23, 2007 that the Board of Directors of the Company at its just concluded meeting has, inter alia, taken the following decisions :- (i) To approve appointment of Mr. Ashok Vij as an Additional Directors of the Company. (ii) To approve appointment of Mr. Vardhan Dharkar, Chief Financial Officer as its new Compliance Officer. The Board also reviewed the progress of Company's upcoming Rs. 100 crores formulation manufacturing facility near Baddi (H.P).

Dabur Pharma Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on September 25, 2006 taken the following decisions:- (i) To approve the Audited Annexure and Proforma prescribed to be attached with the Cost Audit Report on the Cost Accounting Records of the Company for the financial years ended March 31, 2005 and March 31, 2006. (ii) To approve formation of a Wholly Owned Subsidiary Company in Thailand.

Dabur Pharma Limited has informed the Exchange that the Board of Directors at their meeting held on January 27, 2006 has appointed Mr. Irving Kuczynski (Nominee of International Finance Corporation) and Mr. C K Birla as additional Directors on the Board. The Board also took note of the progress of Company's upcoming Rs.100 Crores formulation manufacturing facility near Baddi (HP).

Dabur Pharma Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on April 29, 2005 has inter alia, taken the following decisions: 1) To issue and allot on preferential basis upto 1,22,22,220 equity shares of the face value of Re.1/- each at a price of Rs.54/- per equity share (including premium), to International Finance Corporation, USA. 2) To issue and allot on preferential basis upto 1,50,000 equity shares of the face value of Re.1/- each at a price of Rs.54/- per equity share (including premium), to one or more persons acting as Trustees for Dab